Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
Antitubercular Agents
/ pharmacology
Clofazimine
/ pharmacology
Diarylquinolines
Extensively Drug-Resistant Tuberculosis
/ drug therapy
Humans
Microbial Sensitivity Tests
Mycobacterium tuberculosis
/ genetics
Phylogeny
South Africa
/ epidemiology
Tuberculosis, Multidrug-Resistant
/ drug therapy
United States
Journal
The Lancet. Microbe
ISSN: 2666-5247
Titre abrégé: Lancet Microbe
Pays: England
ID NLM: 101769019
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
ppublish
Résumé
Bedaquiline and clofazimine are important drugs in the treatment of drug-resistant tuberculosis and are commonly used across southern Africa, although drug susceptibility testing is not routinely performed. In this study, we did a genotypic and phenotypic analysis of drug-resistant In this study, we included We sequenced the whole genome of 648 isolates from 385 patients with drug-resistant tuberculosis recruited into cohort studies in KwaZulu-Natal, and 28 isolates from six patients from the KwaZulu-Natal referral laboratory. We identified 30 isolates with Bedaquiline and clofazimine cross-resistance in southern Africa is emerging repeatedly, with evidence of onward transmission largely due to Wellcome Trust, National Institute of Allergy and Infectious Diseases and National Center for Advancing Translational Sciences of the National Institutes of Health.
Sections du résumé
BACKGROUND
Bedaquiline and clofazimine are important drugs in the treatment of drug-resistant tuberculosis and are commonly used across southern Africa, although drug susceptibility testing is not routinely performed. In this study, we did a genotypic and phenotypic analysis of drug-resistant
METHODS
In this study, we included
FINDINGS
We sequenced the whole genome of 648 isolates from 385 patients with drug-resistant tuberculosis recruited into cohort studies in KwaZulu-Natal, and 28 isolates from six patients from the KwaZulu-Natal referral laboratory. We identified 30 isolates with
INTERPRETATION
Bedaquiline and clofazimine cross-resistance in southern Africa is emerging repeatedly, with evidence of onward transmission largely due to
FUNDING
Wellcome Trust, National Institute of Allergy and Infectious Diseases and National Center for Advancing Translational Sciences of the National Institutes of Health.
Identifiants
pubmed: 32803174
doi: 10.1016/S2666-5247(20)30031-8
pii: S2666-5247(20)30031-8
pmc: PMC7416634
doi:
Substances chimiques
Antitubercular Agents
0
Diarylquinolines
0
bedaquiline
78846I289Y
Clofazimine
D959AE5USF
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e165-e174Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R01356X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203583/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203919/Z/16/Z
Pays : United Kingdom
Informations de copyright
© 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Références
EBioMedicine. 2018 Feb;28:136-142
pubmed: 29337135
Tuberculosis (Edinb). 2009 Jan;89(1):84-90
pubmed: 18851927
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32060065
Elife. 2015 Mar 03;4:
pubmed: 25732036
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1564-1568
pubmed: 32053752
J Antimicrob Chemother. 2015 Sep;70(9):2507-10
pubmed: 26045528
Eur Respir J. 2015 Feb;45(2):554-7
pubmed: 25359333
PLoS Med. 2015 Sep 29;12(9):e1001880
pubmed: 26418737
Ann Lab Med. 2018 Nov;38(6):563-568
pubmed: 30027700
Lancet Respir Med. 2017 Apr;5(4):269-281
pubmed: 28109869
Lancet Infect Dis. 2018 Dec;18(12):1350-1359
pubmed: 30342828
J Clin Microbiol. 2015 Nov;53(11):3650-3
pubmed: 26338863
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31262765
PLoS One. 2017 May 18;12(5):e0176522
pubmed: 28545050
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28320727
PLoS One. 2014 Jul 10;9(7):e102135
pubmed: 25010492
Nat Commun. 2014 Sep 01;5:4812
pubmed: 25176035
J Clin Microbiol. 2017 May;55(5):1285-1298
pubmed: 28275074
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690
pubmed: 28031270
Antimicrob Agents Chemother. 2010 Mar;54(3):1022-8
pubmed: 20038615
Antimicrob Agents Chemother. 2014 May;58(5):2979-81
pubmed: 24590481
BMC Med. 2020 Feb 4;18(1):24
pubmed: 32014024
Clin Microbiol Infect. 2017 Apr;23(4):267.e5-267.e7
pubmed: 27998822
J Antimicrob Chemother. 2017 Jul 1;72(7):1901-1906
pubmed: 28387862
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30642938
Arch Intern Med. 1997 Jan 13;157(1):64-9
pubmed: 8996042
Eur Respir J. 2011 Sep;38(3):516-28
pubmed: 21828024
BMC Genomics. 2019 May 20;20(1):389
pubmed: 31109296
Nat Biotechnol. 2019 Feb;37(2):152-159
pubmed: 30718882
Antimicrob Agents Chemother. 2012 May;56(5):2326-34
pubmed: 22354303
Sci Adv. 2018 Oct 17;4(10):eaat5869
pubmed: 30345355
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4590-9
pubmed: 27185800
Lancet Respir Med. 2018 Sep;6(9):699-706
pubmed: 30001994